These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 4024210)
41. Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance. Killilea T; Coleman R; Ludden T; Peck CC; Rose D Ther Drug Monit; 1989; 11(4):455-62. PubMed ID: 2741195 [TBL] [Abstract][Full Text] [Related]
42. The effect of the plasma levels of proteins C and S on the prediction of warfarin maintenance dose requirements. Lubetsky A; Seligsohn U; Ezra D; Halkin H Clin Pharmacol Ther; 1992 Jul; 52(1):42-9. PubMed ID: 1385564 [TBL] [Abstract][Full Text] [Related]
43. Development of a bayesian forecasting method for warfarin dose individualization. Wright DF; Duffull SB Pharm Res; 2011 May; 28(5):1100-11. PubMed ID: 21301936 [TBL] [Abstract][Full Text] [Related]
44. Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. Onundarson PT; Francis CW; Indridason OS; Arnar DO; Bjornsson ES; Magnusson MK; Juliusson SJ; Jensdottir HM; Vidarsson B; Gunnarsson PS; Lund SH; Gudmundsdottir BR Lancet Haematol; 2015 Jun; 2(6):e231-40. PubMed ID: 26688233 [TBL] [Abstract][Full Text] [Related]
45. Variations in prothrombin time and international normalized ratio over 24 hours in warfarin-treated patients. Bleske BE; Welage LS; Warren EW; Brown MB; Shea MJ Pharmacotherapy; 1995; 15(6):709-12. PubMed ID: 8602377 [TBL] [Abstract][Full Text] [Related]
46. Norfloxacin does not alter warfarin's disposition or anticoagulant effect. Rocci ML; Vlasses PH; Distlerath LM; Gregg MH; Wheeler SC; Zing W; Bjornsson TD J Clin Pharmacol; 1990 Aug; 30(8):728-32. PubMed ID: 2401751 [TBL] [Abstract][Full Text] [Related]
47. Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting. Weiss D; Knight R; Zhou S; Palmisano M; Chen N Clin Drug Investig; 2015 Jul; 35(7):455-61. PubMed ID: 26024727 [TBL] [Abstract][Full Text] [Related]
48. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Garrelts JC; Godley PJ; Horton MW; Karboski JA Clin Pharm; 1987 Oct; 6(10):795-9. PubMed ID: 3505841 [TBL] [Abstract][Full Text] [Related]
49. Monitoring warfarin therapy in patients with lupus anticoagulants. Moll S; Ortel TL Ann Intern Med; 1997 Aug; 127(3):177-85. PubMed ID: 9245222 [TBL] [Abstract][Full Text] [Related]
50. Warfarin absorption after massive small bowel resection. Lutomski DM; LaFrance RJ; Bower RH; Fischer JE Am J Gastroenterol; 1985 Feb; 80(2):99-102. PubMed ID: 3970008 [TBL] [Abstract][Full Text] [Related]
51. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Chan E; McLachlan A; O'Reilly R; Rowland M Clin Pharmacol Ther; 1994 Sep; 56(3):286-94. PubMed ID: 7924124 [TBL] [Abstract][Full Text] [Related]
52. The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin. Schwartz JI; Agrawal NG; Hartford AH; Cote J; Hunt TL; Verbesselt R; Eckols DR; Gottesdiener KM J Clin Pharmacol; 2007 May; 47(5):620-7. PubMed ID: 17442687 [TBL] [Abstract][Full Text] [Related]
53. Alteration of warfarin kinetics in man associated with exposure to an operating-room environment. Ghoneim MM; Delle M; Wilson WR; Ambre JJ Anesthesiology; 1975 Sep; 43(3):333-6. PubMed ID: 1163833 [TBL] [Abstract][Full Text] [Related]
54. Comparative pharmacokinetics of coumarin anticoagulants XLV: Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin and phenylbutazone in rats. Yacobi A; Lai CM; Levy G J Pharm Sci; 1980 Jan; 69(1):14-20. PubMed ID: 7354432 [No Abstract] [Full Text] [Related]
55. Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial. Oskarsdóttir AR; Gudmundsdottir BR; Indridason OS; Lund SH; Arnar DO; Bjornsson ES; Magnusson MK; Jensdottir HM; Vidarsson B; Francis CW; Onundarson PT J Thromb Thrombolysis; 2017 May; 43(4):550-561. PubMed ID: 28214948 [TBL] [Abstract][Full Text] [Related]
56. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. Fuder H; Kleist P; Birkel M; Ehrlich A; Emeklibas S; Maslak W; Stridde E; Wetzelsberger N; Wieckhorst G; Lücker PW Eur J Clin Pharmacol; 1997; 53(2):153-7. PubMed ID: 9403289 [TBL] [Abstract][Full Text] [Related]
57. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. Hamberg AK; Hellman J; Dahlberg J; Jonsson EN; Wadelius M BMC Med Inform Decis Mak; 2015 Feb; 15():7. PubMed ID: 25889768 [TBL] [Abstract][Full Text] [Related]